提醒

Puma Biotechnology Inc. (PBYI)

NasdaqGS: PBYI · 实时价格 · USD

8.90

+0.00 (0.00%)

收盘价： Aug 13, 2026, 11:13 AM

0.00% (1D)

买价	6.43
市值	459.42M
营收（TTM）	231.24M
净利润（TTM）	26.72M
贝塔值	1.22
每股收益（TTM）	0.51
市盈率（TTM）	17.45
预期市盈率	25.43
市净率（TTM）	3.28
市销率（TTM）	1.99
Earnings Date	Nov 5, 2026

卖价	11.31
成交量	23,308
20日均量	310,014
开盘价	8.93
前收盘价	8.90
日内区间	8.79 - 8.95
52周区间	4.30 - 9.40
分析师	Hold
目标价	6 (-32.58%)
分红	n/a
除息日	n/a

关于 PBYI

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Apr 24, 2012

员工人数 179

交易所 NasdaqGS

股票代码 PBYI

官网 https://www.pumabiotechnology.com

公司完整简介

财务表现

2025年，Puma Biotechnology的营收为228.37M，较上一年的230.47M下降-0.91%。净利润为31.11M，增长2.75%。

财务报表

分析师预测

根据1位分析师的评级，PBYI的平均评级为“Hold”。12个月目标价为6，较最新价格下跌空间32.58%。

股票预测

财报意外

Puma Biotechnology 已于 Aug 6, 2026 发布季度财报：

营收为 $56.5M 低于预期 $0, ， 7.75% 同比增长.

每股收益为 0.2 超出预期 0.13, ， 33.33% 同比增长.

下次财报发布时间

Puma Biotechnology Inc. 计划于以下时间发布财报 Nov 5, 2026, 盘中。
分析师预计营收为 ... 升级

新闻

21小时前 · Zacks

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

5天前 · Zacks

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

5天前 · Moby

Puma Biotechnology, Inc. Q2 2026 Earnings Call Summary

Moby summary of Puma Biotechnology, Inc.'s Q2 2026 earnings call

6天前 · MarketBeat

Puma Biotechnology Q2 Earnings Call Highlights

Puma Biotechnology (NASDAQ:PBYI) reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The compa...

6天前 · GuruFocus.com

Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ...

Puma Biotechnology Inc (PBYI) posts $8.2 million GAAP net income, raises full-year revenue and profit outlook, and advances its alisertib clinical program.

第 1 页，共 2 页

Puma Biotechnology Inc. (PBYI)